Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction

Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction

Although capillary leak syndrome has a high mortality rate, its trigger, diagnosis, and treatment remain a challenge to clinicians because of the poor understanding of its mechanism and lack of treatment guidelines. With the extended use of immune checkpoint inhibitors in modern oncology, immune che...

Full description

Bibliographic Details
Main Authors: Haixia Qin, MD, PhD, Brittany Vlaminck, CNP, Itunu Owoyemi, MBBS, Sandra M. Herrmann, MD, Nelson Leung, MD, Svetomir N. Markovic, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S2542454821000047
Description
Summary:Although capillary leak syndrome has a high mortality rate, its trigger, diagnosis, and treatment remain a challenge to clinicians because of the poor understanding of its mechanism and lack of treatment guidelines. With the extended use of immune checkpoint inhibitors in modern oncology, immune checkpoint inhibitor–associated immune-related adverse events have also expanded. We present a case of pembrolizumab-induced capillary leak syndrome and lymphatic capillary dysfunction in which the patient had an excellent clinical response to a tailored treatment strategy.
ISSN:2542-4548

Similar Items